Federal health officials report that Candida auris, a deadly drug-resistant fungus, has been detected in 27 U.S. states with 3,437 clinically confirmed cases as of late July 2026.
Tracking the Spread and 2026 Case Projections
Cases of the deadly, drug-resistant fungus are spreading across the United States, according to data from the Centers for Disease Control and Prevention. Roughly 3,437 clinically confirmed cases across 27 states were logged as of the week ending July 25. That total runs about 1,000 cases behind the pace recorded during the exact same week last year, yet the trajectory tells a different story.
The current pace of emerging infections puts the country on track to reach 2025’s full-year total of 4,290 infections before the end of 2026. Federal data indicates that detected infections have climbed every single year since 2019. The sharpest annual spike arrived between 2022 and 2023, when numbers surged by 53.7 percent.
Public health authorities emphasize that rising case numbers do not automatically mean an absolute surge in total infections. More robust screening protocols and earlier clinical diagnoses also account for a meaningful share of the upward climb.
Regional Hotspots and State-Level Impacts
Geography plays a major role in how the fungus moves through populations. The Pacific region, encompassing Alaska, California, Hawaii, Oregon, and Washington, carries the heaviest regional load with 886 cumulative cases.
California alone accounts for 873 single-state infections reported during the week ending July 25. Meanwhile, states like Kentucky have also logged infections, reporting seven confirmed cases within that same timeframe.
Understanding the Pathogen and Patient Risk Factors
Candida auris manifests as a yeast rather than a naturally occurring organism on the human body. It spreads primarily inside hospitals and long-term care facilities through direct contact with infected individuals or contaminated surfaces.
Healthy immune systems typically fend off the infection. However, the fungus poses severe risks to immunocompromised individuals, potentially causing life-threatening sepsis or mild skin infections alike.
“Most patients who become sick with C. auris were already very sick,”
Centers for Disease Control and Prevention
Major risk factors involve invasive medical interventions. Patients relying on breathing tubes, feeding tubes, and catheters face heightened vulnerability.
“When patients with C. auris die, it is hard to know how much C. auris contributed to their death compared to other pre-existing illnesses.”
Centers for Disease Control and Prevention
Treatment Obstacles and Antifungal Resistance
Treating the pathogen presents a steep challenge for clinicians. A CDC analysis of an outbreak spanning 2022 to 2023 revealed that 95 percent of samples resisted fluconazole, the standard first-line antifungal treatment.
While alternative medications like echinocandins frequently succeed, certain strains have begun showing resistance to those drugs as well. Consequently, doctors occasionally combine multiple medications to establish an effective defense.
Because the fungus was first identified in the United States in 2016, researchers are still racing to understand its full clinical scope. Mortality rate estimates range widely from roughly 30 percent to over 60 percent, complicated by the severe underlying health conditions of those who contract it.
Mitigation Strategies in Medical Environments
Because carriers can harbor the fungus on their skin without showing any symptoms, the organism can travel undetected between patients and rooms.
Health agencies maintain that infections remain relatively rare outside of clinical facilities. Stopping transmission relies heavily on strict sanitation, careful equipment sterilization, hand hygiene, and targeted patient isolation when exposure is confirmed.
